Src-homology region 2 (SH2) domains, by binding to tyrosine-phosphorylated sequences, mediate specific proteinprotein interactions important in diverse signal transduction pathways. Previous studies have shown that activated forms of the A b 1 tyrosine kinase, including P210""' of human chronic myelogenous leukemia, require the SH2 domain for the transformation of fibroblasts. To determine whether SH2 is also required for Bcr/Abl to transform hematopoietic cells, we have studied two SH2 domain mutations in P210-m: a point mutation in the conserved FLVRES motif (P210/R1053K), which interferes with phosphotyrosine-binding by SH2, and a complete deletion of SH2 (P210/ ASH2). Despite a negative effect on intrinsic Ab1 kinase activity, both P210 SH2 mutants were still able to transform
HE PHILADELPHIA chromosome is the result of a reciprocal translocation in which the c-ABL gene on chromosome 9 is truncated at its 5' end by BCR sequences from chromosome 22, forming the chimeric gene BCW ABL.'.' BCWABL has been implicated in a wide range of human leukemias, including virtually all cases of chronic myelogenous leukemia (CML), approximately 20% to 30% of adult acute lymphoblastic leukemia (ALL), and less commonly acute myelogenous le~kemia.~ The normal cellular function of the BCR gene is unknown, but c-ABL, the cellular homologue of the transforming gene of Abelson murine leukemia virus, encodes a non-receptor protein-tyrosine kinase. The normal c-Ab1 protein is unable to transform cells, even when over-expressed4; however, the fusion protein Bcr/Abl exhibits increased tyrosine kinase activity5 and gains the ability to cause cellular transformation in several assays, including focus formation and soft agar colony growth in fibroblasts: transformation of hematopoietic factor-dependent cell lines to growth factor independence:* transformation of bone marrow cells in vitro: and induction of leukemia in mice.Ia1' c-Abl, like many other proteins implicated in signal transduction, contains a Src homology region two (SH2) domain.I3 These domains are non-catalytic regions, approximately 100 amino acids in length, that bind with high affinity to specific amino acid sequences containing phosphorylated tyrosine residue^.'^"^ The phosphotyrosine-binding function of SH2 is crucial for fibroblast transformation by ABL. A point mutation in the highly conserved FLVRES motif of the Ab1 SH2 domain, resulting in an arginine to lysine change at position 171 (R171K) in the phosphotyrosine binding site,I7 blocks binding of SH2 to phosphotyrosine-containing proteins in vitro and greatly decreases fibroblast transformation in vivo by activated c-Abl.'* Complete deletion of the SH2 domain of activated c-Ab1 abolishes fibroblast transformation." An analogous point mutation (R552L) in the SH2 domain of P185BcR/ABL, the form of BCRLABL most commonly seen in Philadelphia chromosome-positive ALL, impairs Rat-l fibroblast transformation. 20 These studies demonstrate that activated forms of Ab1 require the SH2 domain for the transformation of fibroblasts.
Because BCRLABL is associated with hematopoietic ma- lignancies, it is important to determine whether the SH2 domain is also required for hematopoietic cell transformation and leukemogenesis by P2108cwABL. A previous report suggested that the Ab1 SH2 domain may be dispensable for the transformation of a hematopoietic cell line?' We have generated P21OBcwABL mutants containing either a FLVRES point mutation (P210/R1053K), or a complete deletion of the SH2 domain (P210/ASH2), and have examined their ability to transform the hematopoietic factor-dependent cell lines Ba/F3 (a murine pro-B lymphoid cell line") and FDC-P1 (a murine early myeloid cell linez3). Although P210/ R1053K and particularly P210/ASH2 exhibit significantly decreased intrinsic kinase activity relative to P2108cwABL, they were still able to transform Ba/F3 and FDC-P1 cells to growth factor independence. Unexpectedly, both P210 SH2 mutants exhibited a higher transforming activity than wildtype P210 in a quantitative transformation assay, and retained the ability to induce leukemia in syngeneic mice, although P210/R1053K mice exhibited a distinct disease phenotype.
MATERIALS AND METHODS

Construction of BCWABL SH2 Domain Mutants
The P210/R1053K mutant was constructed using site-specific mutagenesis using the MutaGene Phagemid system (Bio-Rad Labora-tones, Melville, NY), based on the method of Kunkel et al.'" The mutagenic primer (5' GCAGCTTCTTAGTGAAGGAGAGTG-AGAGTAGCCCGGGCCAGAGATCCATC 3') was hybridized to a single-stranded, uracil-containing, P2 1 HindIII fragment contained in the vector pTZ19U. The primer contained a new Hpu I1 site to identify mutant clones. The P210/R1053K mutant was confirmed by dideoxy DNA sequencing, and the HindIII fragment was subcloned into the vector pGDARI, which is identical to the vector pGD," but lacks the EcoRI site in the neomycin resistance gene cassette.
The P210/ASH2 mutant was generated through a series of restriction digests in which the HinPI site at nucleotide #804 and the Kpn I site at #527" were blunt-ended and fused in-frame, resulting in the deletion of the SH2 domain from amino acid #l030 to #l 120 in the K562 b3a2 cDNA. The mutation was verified by dideoxy DNA sequencing and restriction mapping was performed to confirm preservation of the Kpn I site. The mutant cDNA was subcloned into pGDARI for transfection.
Cells and Cell Culture
Ba/F3 and FDC-P1 cells were grown in liquid culture at 37°C and 5% CO2 in Dulbecco's modified Eagle's medium (DME-high) containing 10% heat-inactivated fetal calf serum, penicillinktreptomycin, and 2 mmoVL glutamine. Where indicated, the medium was supplemented with growth factor in the form of either 5% to 10% (voVvol) WEHI-3B-conditioned medium as a source of interleukin 3 (IL-3)26 (Ba/F3 and FDC-PI cells), or murine recombinant granulocyte macrophage colony-stimulating factor (GM-CSF; Immunex, Seattle, WA) at a concentration of 30 U/mL (FDC-PI cells). BOSC-23 cells2' were grown in DME-high containing 10% heat-inactivated fetal calf serum, penicillinheptomycin, 2 mmoVL glutamine, and nonessential amino acids.
Gene Transfer
Retrovirul infection. Ten micrograms of P210 or SH2 domain mutant DNA in the retroviral expression vector pGDAR1," which contains a gene encoding resistance to neomycin, was introduced into the retroviral packaging cell line BOSC-23 by calcium phosphate transfection, as described." Twelve to 16 hours later, 6 X IO6 Ba/F3 cells were gently added to each 10 cm BOSC-23 plate in the presence of 6 pg/mL hexadimethrine bromide (Polybrene; Sigma, St Louis, MO) and 10% WEHI-3B conditioned medium. The titers of the retroviral stocks did not differ significantly between P210 and the SH2 mutants, and was in the range that yields single copies of the BCWABL genome in recipient cells. After 36 hours of co-cultivation the Ba/F3 cells were removed, transferred to tissue culture flasks, and selected in the presence of growth factor in 1 mg/mL neomycin (absolute).
Electroporution. Because FDC-PI cells were relatively resistant to BOSC-23 cell retroviral infection, electroporation was used. Approximately 8 to 12 X IO6 exponentially growing FDC-P1 cells were washed twice in ice cold phosphate-buffered saline lacking calcium and magnesium chloride (PBS-), and resuspended in 800 ML of PBS-. All DNA was twice purified by buoyant density centrifugation in cesium chloride. Fifty micrograms of linearized P210 or SH2 domain mutant DNA in pGDARI was then added to the cells. Electroporation conditions were 220 volts and 960 pFarads (time constant: 17 to 22.5 msec), using a Bio-Rad Genepulser apparatus. After electroporation, the cells were placed on ice for 5 to IO minutes and then allowed to recover in nonselective medium for 24 hours at 37°C. Selection was then performed in the presence of growth factor in 0.3 mg/mL neomycin (absolute) in a 75 cm2 tissue culture flask. By day 9 to 11 a confluent population of neomycin resistant cells was obtained for subsequent cloning by limiting dilution.
Analysis of Clones ,for Growth Factor Independence
Neomycin resistant populations of BaF3 or FDC-PI cells, containing P210 or one of the SH2 domain mutants, were cloned by limiting dilution into 96-well plates. Clones were isolated in the presence of growth factor and neomycin, with fresh medium added every 3 days to prevent any possibility of growth factor depletion. After approximately I O days the wells were sufficiently confluent to be harvested. The cells were gently pelleted in 1.6 mL eppendorf tubes, washed twice in P B S , and distributed equally into parallel 24-well plates containing medium with or without supplemental growth factor. After 48 to 72 hours, the 24-well plates were scored by counting the number of clones capable of factor-independent growth. A growth factor-independent clone was defined as a clone that was able to proliferate both in the presence and absence of supplemental growth factor. Analysis of individual growth factor-independent clones by Southern blot revealed that the majority possessed a single copy of the BCWABL gene. The data were expressed as a ratio of the number of factor-independent clones divided by the total number of clones analyzed. The proportions obtained from hematopoietic factor-dependent cell lines containing the BCWABL SH2 domain mutants were compared with those containing wild-type P210, and analyzed using a x' test for significance.
Autocrine Growth Analysis
(A) Conditioned media obtained from growth factor-independent populations of Ba/F3 and FDC-P1 cells expressing P210 or one of the SH2 mutants was concentrated 25-to 30-fold using centriprep-IO ultrafiltration (Amicon, Beverly, MA), and added to duplicate samples of 10' parental Ba/F3 or FDC-PI cells at a concentration of 10% (vollvol) in standard medium without growth factor. The viable cell count was determined daily. (B) Neutralizing monoclonal anti-IL-3 antibody (Genzyme, Cambridge, MA) was added to growth factor-independent populations of Ba/F3 or FDC-P1 cells expressing P210 or one of the SH2 mutants at a concentration (IO pg/mL) 10-fold higher than was required to cause growth arrest of Ba/F3 cells and death of FDC-P1 cells growing in 1% WEHI-3B-conditioned medium. Viable cells were counted daily and their growth rate compared with cells grown in the absence of neutralizing antibody.
RNA Analysis
Total RNA was prepared from populations of neomycin-resistant Ba/F3 cells transfected with P210 or the SH2 mutants, before and after selection for the growth factor-independent phenotype, using the guanidinium isocyanate method.28 Equal amounts of total RNA were subjected to denaturing agarose gel electrophoresis, transferred to a nylon membrane, and hybridized with a 3zP-labeled DNA probe generated from a 1,100-bp Clu I fragment from the neomycin gene cassette contained in the pGDARI vector."
In Vitro Kinase Assay
P210, P210/R1053K, or P210ASH2, contained in the vector PJ3Clz9 were introduced into 293T cells3' by transient transfection; alternatively, growth factor-independent Ba/F3 cells were used as the source of Bcr/Abl protein. Lysates were made and normalized by western blot for the amount of Bcr/Abl protein using the antiAb1 monoclonal antibody 19-84.31 Equal amounts of Bcr/Abl proteins were subjected to immunoprecipitation with anti-GEX4 antisera (recognizing COOH-terminal Ab1 sequence^^^), and an immune complex kinase assay performed as previously described,* with enolase added as an exogenous substrate." The proteins were then separated on a 5% to 9% gradient sodium dodecyl sulfate (SDS)-polyacrylamide gel, detected by autoradiography, and quantitated using a phosphorimager (GS-250; Bio-Rad Laboratories). 
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RESULTS
Ab1 SH2 Mutations Attenuate Bcr/Abl Kinase Activity In Vitro
To examine the effect of mutations in SH2 on the tyrosine kinase activity of P210, we expressed P210 and SH2 mutant proteins in 293T cells and performed an immune complex kinase assay. Addition of Bcr sequences to the NH2-terminus of Ab1 increases the intrinsic tyrosine kinase activity of the protein." Relative to c-Abl, P210 kinase activity was increased approximately six-fold, while P190, the form of Bcd Ab1 most commonly associated with Philadelphia chromosome-positive ALL, was elevated almost ten-fold, consistent with previous observation^'^ (Fig l) . The mutation disrupting directly in neomycin, the efficiency of recovery of neomycinresistant clones was similar with either parental pGDAR1 vector alone, P210, or the SH2 mutants, suggesting there was no significant lethal or cytotoxic effect of transfection of Bcr/Abl in these cells.3"3R Cells incapable of growth in the absence of L 3 or GM-CSF generally died within 24 hours of growth factor deprivation. No Ba/F3 or FDC-PI cells spontaneously acquired the ability to grow without growth factor (data not shown). Further, neither pGDARI vector alone nor a kinaseinactive mutant of Ab1 supported any factor-independent growth (data not shown), confirming that the tyrosine kinase activity of Ab1 is required for the transformation of factordependent hematopoietic cells.39
The ratio of growth factor-independent clones to total number of clones was calculated for each of the P210 mutants, and compared with wild-type P210 (Table I) .
conferred growth factor independence on approximately 25% and 23% of transfected BaF3 and FDC-P1 clones, respectively. Surprisingly, both SH2 domain mutants not only retained the ability to confer growth factor independence on these cells, but also exhibited approximately twice the transforming activity of wild-type P210; P21OBCwAB', P210 containing an FLVRES mutation (P210/R1053K), or P210 containing an in-frame deletion of the entire SH2 domain (P210/ASH2) were introduced into the hematopoietic factor-dependent cell lines Ea/F3 and FDC-P1 by retroviral gene transfer or electroporation. Individual clones were isolated by limiting dilution in the presence of growth factor (GF+), and then analyzed by the ability to grow in medium lacking supplemental growth factor (GF-). t P < .02, for SH2 mutants compared to wild-type P210, using a x* test comparing two proportions.
approximately 46% to 50% of clones containing the point mutation that severely impairs phosphotyrosine binding (P210/R1053K), and 47% to 49% of clones lacking the Ab1 SH2 domain entirely (P210/ASH2) were capable of growth factor-independent growth. The differences between P210 and the SH2 domain mutants were statistically significant ( P < .02, using a x ' test comparing two proportions). In the case of the FDC-P1 cells, there was no significant difference in the ability of clones to grow in the absence of either IL-3 (WEHI-3B-conditioned medium) or GM-CSF (data not shown). Therefore, in contrast to fibroblast transformation, neither the phosphotyrosine-binding function of SH2 nor the SH2 domain itself was required for BCWABL to transform these hematopoietic factor-dependent cell lines to growth factor-independent proliferation.
To investigate the possibility that autocrine secretion of IL-3 was responsible for induction of factor-independence by P210 or the SH2 mutant^,^ we tested the ability of conditioned medium from transformed cells to support the growth of the parental BaF3 and FDC-P1 cells, and the effect of neutralizing anti-IL-3 antibodies on their growth. High concentrations of conditioned medium from Ba/F3 or FDC-P1 cells expressing P210/R1053K supported the growth of parental FDC-P1 cells, consistent with secretion of IL-3 or GM-CSF (data not shown). We were unable to detect similar growth-promoting activity in conditioned medium from cells expressing wild-type P210 or the P210 ASH2 mutant. However, neutralizing anti-IL-3 antibodies, added at levels tenfold higher than necessary to induce apoptosis of parental BaF3 or FDC-P1 cells in 1% WEHI-3B conditioned medium, did not affect the proliferation of factor-independent cells transformed by P210, P210/R1053K, or P210/ASH2 (data not shown). Therefore, autocrine production of IL-3 does not play a role in the induction of growth factor independence by P210 or the SH2 mutants, consistent with previous observation^.^,^
BdF3 Cells Transformed by P210 SH2 Mutants Express Higher Levels of Bcr/Abl Protein, But Exhibit Similar Levels of Phosphotyrosine on Bcr/Abl
Polyclonal populations and individual clones of factorindependent cells expressing wild-type and mutant forms of p21 0BCWABL were analyzed by Western blot for levels of Bcr/ Ab1 expression and pattern of protein tyrosine phosphorylation. Most of the clones that were incapable of factor-independent growth failed to express detectable Bcr/Abl protein. Some factor-dependent clones expressed low levels of Bcr/ Abl, generally less than 5% of the amount of Bcr/Abl protein found in cells capable of factor-independent growth, and at about the same level as endogenous c-Ab1 (data not shown). This suggests that a threshold level of Bcr/Abl is necessary to overcome the requirement for growth factor, analogous to an effect documented for v-Src transformation of fibroblast~.~' In factor-independent cells, the total level of Bcr/ Ab1 protein was approximately twofold higher for both P21 0/ R1053K and P210/ASH2 compared with wild-type P210 (Fig 2A) ; however, the level of phosphotyrosine on Bcr/Abl was more similar, perhaps due to the decreased kinase activity of the SH2 mutants (Fig 2B) . Interestingly, the increased level of Bcr/Abl protein expression by the SH2 mutants was evident even before selection for growth factor independence (Fig 2C) , while the relative levels of BCWABL mRNA were similar between the SH2 mutants and wild-type P210 ( Fig  2D) before and after selection for growth factor independence. There was a general increase in expression of both Bcr/Abl mRNA and protein following selection for growth factor independence, consistent with a threshold requirement for transformation. These results suggest that the elevated expression of the Bcr/Abl SH2 mutant proteins may be due to increased protein stability. We could not demonstrate any significant decrease in the level of mutant or wild-type Bcr/ Ab1 protein even after over 24 hours of treatment with cycloheximide (data not shown), consistent with the known long half-life of P210.4'
The overall pattern of phosphotyrosinated proteins was quite similar between P210 and the SH2 domain mutants, except that R1053K-expressing clones frequently demonstrated decreased tyrosine phosphorylation of proteins migrating at 120 and 60 kd, which are likely p120 rasGAP (GTPase-activating p r~t e i n )~' .~~ and p62 rasGAP-associated respectively. These proteins have been shown to be tyrosine-phosphorylated in cells transformed by various tyrosine kinase oncogenes, including BCWABL.46.47 Decreased tyrosine phosphorylation of p62 has also been reported in fibroblasts transformed by a BCWABL SH2 point mutant.*' The overall pattern of Bcr/Abl expression and protein tyrosine phosphorylation seen in P210 and the SH2 domain mutations did not differ significantly between BaF3 and FDC-P1 cells (data not shown), suggesting that these findings are not peculiar to one hematopoietic lineage.
The P210/Rl053K Mutant Exhibits a Distinct Disease Phenotype in an In Vivo Leukemogenesis Assay
The transformation of B e 3 cells to growth factor independence by P210 has been previously shown to correlate with their ability to form tumors after subcutaneous inoculation into athymic (nude) mice.' Because the BaF3 cell line was originally derived from BALB/c mice," these animals provide a convenient in vivo model to explore P210BCWABL-mediated leukemogenicity. Intravenous injection of lo5 BALB/c mice within 16 days (Van Etten et al, in preparation). Autopsy of diseased animals reveals an overwhelming leukemia, with diffuse replacement of bone marrow, liver, and spleen with cells that morphologically resemble the input BaF3 cells (data not shown). Injections of factor-dependent parental BaF3 cells have yielded no disease in recipient mice followed for up to 3 months.
P210-transformed BaF3 cells causes death in all recipient
The clinical manifestations or latency of BCWABL-associated illness did not differ significantly between mice that received BaF3 cells transformed by P210 or P210/ASH2, with all animals dying secondary to a diffuse leukemic process between days 15 and 16. In contrast, mice that received cells transformed by the SH2 point mutant P210/R1053K demonstrated a significantly longer latency, with all animals succumbing by day 26 (Fig 3) . This was unlikely to be due to a difference in growth rate, because all three cell populations grew at similar rates in culture (data not shown). In addition to the longer latency period, mice receiving BaF3 cells transformed by P210/R1053K exhibited a distinct disease phenotype, with approximately two-thirds of animals developing a hind-limb paralysis syndrome before death. This condition, which is characteristic of adult BALB/ c mice infected with Abelson murine leukemia virus and reflects compression of the lumbar spinal cord nerve roots due to leukemic involvement of the paraspinous lymph node chain:' was never observed in recipients of P210-or P2101 ASH2-transformed BaF3 cells.
DISCUSSION
The interaction of SH2 domain-containing proteins with specific phosphotyrosinated sequences has been shown to be important for signal transduction involving both receptor and nonreceptor protein-tyrosine kinases. Previous studies have shown that the SH2 domain of activated forms of Ab1 is required for fibroblast transformation. We have studied two SH2 domain mutants, P210/R1053K, which contains a point mutation interfering with phosphotyrosine-binding by SH2, and P210/ASH2, lacking the entire domain. In contrast to the findings in fibroblasts, both SH2 mutants are more highly transforming than wild-type P210 in the hematopoietic factor-dependent cell lines BaF3 and FDC-PI, despite decreased intrinsic kinase activity. These results confirm a previous report that noted that a population of BaF3 cells transfected with an SH2-deleted form of BCW ABL was able to grow in the absence of growth factor." Others have also recently found FDC-P1 cells to be transformed by BCWABL lacking an SH2 domain. 49 The tyrosine kinase function of Ab1 is required for Bcr/ Ab1 transformation of hematopoietic factor-dependent cell lines39 (data not shown). The mechanism by which Bcr activates the Ab1 kinase is unknown, but in fibroblasts may be related to its interactions with Ab1 SH2. Bcr first exon sequences have been shown to bind Ab1 SH2 in vitro in a phosphotyrosine-independent fashion, and deletion of these regions in Bcr abolished fibroblast tran~formation.~' We have found that the tyrosine-binding function of SH2 (P210/ R1053K) is not required for the activation of the Ab1 tyrosine kinase, while complete deletion of SH2 abrogated the activation of the Ab1 kinase by Bcr in vitro, consistent with this model. However, deletion of SH2 did not interfere with Bcr/ Ab1 transformation of factor-dependent hematopoietic cell lines. These findings suggest that other functions of Bcr, such as oligomerization," may be important for transformation of hematopoietic cells by BCWABL. A lack of correlation between Ab1 kinase activity in vitro and transformation ability in vivo has also been observed for SH3-deleted c-Abl, which is potent in cellular transformation despite the same kinase activity as c-Ab1 in v i t r~.~~~~~ Although the P210/ ASH2 mutant showed about sixfold lower in vitro autophosphorylation activity than wild-type P210, when isolated from transformed hematopoietic cells the degree of tyrosine phosphorylation of the ASH2 mutant was more similar to that of wild-type P210 (about twofold lower). This suggests that the tyrosine kinase activity of P210/ASH2 is higher in vivo than in vitro, or that the susceptibility of the ASH2 protein to tyrosine phosphatases in vivo is reduced.
Hematopoietic cells and fibroblasts have been shown to require distinct functions of Ab1 for transformation. Activated forms of Ab1 lacking the membrane-targeting myristoylation domain," or containing a point mutation in an autophosphorylation site within the P210BCwABL lunase domain (Y1294F)'9 are defective in fibroblast transformation, but retain the ability to transform factor-dependent cell lines. Similarly, while the SH2 domain is essential for fibroblast transformation by Abl, it is dispensable for the BCWABL transformation of BaF3 or FDC-P1 cells. BCWABL signal transduction may involve different pathways, or emphasize particular mediators, depending on cell type. In fibroblasts the Ab1 SH2 domain may bind specific tyrosine-phosphorylated proteins that transduce signals required for transformation, while in hematopoietic factor-dependent cell lines this SH2-mediated signaling pathway is not required, or is regulated differently. Alternatively, the Ab1 SH2 domain might serve to protect phosphotyrosine sites on substrates from the action of phosphatases," which might have different consequences in fibroblasts and hematopoietic cells.
Using a quantitative transformation assay we have found that both P210 SH2 domain mutants are actually more transforming than wild-type P210. There are several possible explanations for this finding. One possibility is that P210 SH2 mutants have decreased cytotoxicity. A growth inhibitory or toxic effect has been observed with expression of c-Abl, vAbl, and Bcr/Abl in fibroblasts,'6"K which may be dependent on SH2.'8 Therefore, mutations in SH2 may decrease this toxic effect of Bcr/Abl expression and allow increased recovery of transformed clones. However, we found no significant difference in the frequency of neomycin-resistant clones transformed with vector DNA alone or with wild-type or SH2 mutant forms of P210, suggesting that Bcr/Abl does not exhibit prominent toxicity in hematopoietic cells (data not shown). A more likely possibility is related to our observation that there is a threshold level of Bcr/Abl necessary for Ba/F3 transformation, analogous to Src transformation. We found that populations of Ba/F3 cells transfected with the SH2 mutants expressed higher levels of Bcr/Abl protein even before selection for growth factor independence, which could explain their greater transforming ability in this assay. Because P210 and the SH2 mutants had similar BCWABL mRNA levels by northern blot, this suggests a post-translational effect, such as increased stability of the SH2 mutant proteins, was responsible for the increased expression. We were not able to demonstrate any significant decrease in the level of mutant or wild-type Bcr/Abl proteins even with prolonged cycloheximide treatment, which probably reflects the relatively long half-life of P210, as has been noted by other^.^' The loss of SH2 function may affect the interaction of Bcr/Abl with another protein(s), which normally serves to regulate its stability.
The Ab1 SH2 domain is also not required for leukemogenicity of P210-BaiF3 cells in vivo. Mice inoculated intravenously with Ba/F3 cells transformed by P210 of the ASH2
For personal use only. on . by guest www.bloodjournal.org From mutant die from an overwhelming leukemia by day 16, with infiltration of bone marrow, liver, and spleen. Interestingly, the SH2 domain point mutant P210R1053K demonstrated a distinct disease phenotype, manifested by a greater latency of illness (death by day 25) and the frequent development of a syndrome of lower extremity paresis due to paraspinous lymph node infiltration, not seen in wild-type or P210/ASH2 disease, but reminiscent of classic disease induced by the Abelson virus. These findings raise the possibility that interference with the phosphotyrosine-binding function of mechanisms for this remain speculative, but may reflect alternative signal transduction pathways used by P2101 R1053K, perhaps related to the differences in protein tyrosine phosphorylation of p 120 rasGAP and p62 rasGAP-associated proteins seen on Western blot.
In summary, while the Ab1 SH2 domain is essential for BCWABL transformation of fibroblasts, it is dispensable for the transformation of hematopoietic factor-dependent cell lines. Transformation of fibroblasts may require a specific signal mediated by the Ab1 SH2 domain, which is not required for induction of growth factor independence in hematopoietic factor-dependent cell lines. Compared with wild-type P210, the P210R1053K mutant demonstrated differences in both the pattern of protein tyrosine phosphorylation and leukemic phenotype in vivo. Whether these two phenomena are related, or reflect a physiologic difference between phosphotyrosine binding and other functions of Ab1 SH2, remains to be investigated. It will be important to determine whether the Ab1 SH2 domain is required for BCW ABL-induced leukemia in humans. This issue is particularly relevant if the Ab1 SH2 domain is to be considered a target for rational drug design for the therapy of patients afflicted with these diseases. Experimental models that permit the analysis of P210 SH2 domain mutants in the context of early hematopoietic stem cells" may help resolve this issue. p2 1oBCWABL may affect cell homing in vivo. The possible
